30% More Genetic Toxicology Space
Your continuing requirements to find new options for product testing inspired us to grow our capacity for genetic toxicology and in vitro alternatives. It’s an investment focused on enabling you to quickly and effectively respond to changing regulatory requirements as well as the evolving industry sentiments regarding product testing. And it’s enabling our researchers to innovate faster around the 3Rs principles (replacement, reduction and refinement) with a keen focus on bringing you more in in vitro alternatives and robotic-driven study solutions.
In order to provide more access to cutting-edge in vitro solutions, the size of our genetic toxicology labs in Harrogate, U.K. has been expanded by more than 30 percent. In addition, new spaces are now open at our U.K. sites in Shardlow and Huntingdon to provide you with even more options. By broadening study capacity for you, our investment is creating a sustainable evaluation process rooted in the 3Rs that’s adaptable for many different industries’ product development pipelines.
“It’s all about enabling our customers to develop safe products. Whether that is a pharmaceutical, chemical, cosmetic, aerosol or medical device,” says Julie Clements, Global Lead of Genetic Toxicology. We are driven by a focus on humanity–enhancing testing methods to ensure safer products and a safer world.
With the new space comes a suite of innovative assays to look at different endpoints from cardiovascular to pulmonary. By exploring cell cultures, 3D tissues, in vitro alternative methods and options for screening flow cytometry for multi-endpoint assays that go beyond a “yes” or “no” answer, we can reveal more insightful mechanistic information.
Your research at the expanded genetic toxicology facilities is already garnering positive results. “Collaborating with customers to push the boundaries in science is what keeps customers coming back,” says Joanne Miller, Executive Director Global Crop Protection and Chemical Sales. “Because they know they’re getting scientific expertise from a team that has their ears to the ground about what’s coming up next.”
One exciting area of growth is in aerosol science. We are exploring cutting-edge solutions and robotics that comply with new regulations and provide models of human tissues. “By using airway 3D models, oral tissue models and lung tissue models, these breakthroughs can bridge the gap between in vivo and in vitro,” explains Miller.
As the world’s demand for safe products increases, the demand for innovation in genetic toxicology and in vitro models increases along with it. In our aim to be more than a partner, we have not only recognized this need. We have transcended it. Our recent investment in genetic toxicology is already resulting in flexible solutions for novel practices within our laboratories, which means safe products for consumers. And we see a bright future ahead.